Bain Capital Public Equity Management LLC lowered its position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 10.7% during the fourth quarter, Holdings Channel reports. The fund owned 328,113 shares of the company’s stock after selling 39,201 shares during the period. Bain Capital Public Equity Management LLC owned about 1.07% of Spark Therapeutics worth $16,373,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Spark Therapeutics by 0.5% in the fourth quarter. FMR LLC now owns 4,615,957 shares of the company’s stock worth $230,336,000 after buying an additional 22,784 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Spark Therapeutics by 28.9% in the second quarter. Vanguard Group Inc. now owns 1,512,600 shares of the company’s stock worth $77,340,000 after buying an additional 338,720 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Spark Therapeutics during the third quarter worth $79,180,000. State Street Corp boosted its stake in shares of Spark Therapeutics by 12.4% in the fourth quarter. State Street Corp now owns 902,606 shares of the company’s stock worth $45,044,000 after buying an additional 99,792 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Spark Therapeutics by 17.8% in the third quarter. BlackRock Fund Advisors now owns 894,515 shares of the company’s stock worth $53,725,000 after buying an additional 135,009 shares in the last quarter. 83.97% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) traded down 0.62% during trading on Thursday, reaching $64.57. The company had a trading volume of 262,050 shares. The firm has a 50 day moving average price of $59.82 and a 200 day moving average price of $56.95. Spark Therapeutics, Inc. has a 12 month low of $28.38 and a 12 month high of $65.99. The company’s market cap is $1.99 billion.

This article was originally posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The original version of this article can be read at http://www.dailypolitical.com/2017/02/16/bain-capital-public-equity-management-llc-reduces-position-in-spark-therapeutics-inc-once.html.

A number of analysts have weighed in on the company. Jefferies Group LLC reaffirmed a “hold” rating and issued a $57.00 price target on shares of Spark Therapeutics in a research report on Tuesday, January 10th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 price target on shares of Spark Therapeutics in a research report on Friday, November 4th. Zacks Investment Research cut Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 14th. Chardan Capital reaffirmed a “neutral” rating and issued a $47.50 price target (down previously from $55.00) on shares of Spark Therapeutics in a research report on Monday, November 7th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Monday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $62.43.

In other news, Director Anand Mehra sold 25,334 shares of the stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $65.06, for a total transaction of $1,648,230.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Barge Joseph La sold 3,000 shares of the stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $52.98, for a total transaction of $158,940.00. Following the transaction, the insider now owns 8,325 shares of the company’s stock, valued at $441,058.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 500,522 shares of company stock valued at $27,259,870. Company insiders own 9.60% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.